July 1990

Radioimmune Localization of Occult Carcinoma

Author Affiliations

Denise Webber
From the Departments of Surgery (Dr Duda), and Medicine (Dr Rosen and Ms Gilyon) and the Division of Nuclear Medicine (Drs Zimmer, S. Spies, and W. Spies and Ms Webber), Northwestern University Medical School, Northwestern Memorial Hospital, Chicago, Illinois; and Hybritech Inc, San Diego, Calif (Dr Merchant).

Arch Surg. 1990;125(7):866-870. doi:10.1001/archsurg.1990.01410190064010

• Patients with a rising serum carcinoembryonic antigen level and no clinical or roentgenographic evidence of recurrent or metastatic cancer present a treatment dilemma. Eleven such patients, 10 with a previously treated colorectal carcinoma and 1 with a previously treated breast carcinoma, received an injection of the anticarcinoembryonic antigen monoclonal antibody ZCE-025 labeled with the radioisotope indium 111. Nuclear scintigraphy was performed on days 3 and 5 through 7 to detect potential sites of tumor recurrence. The monoclonal antibody scan accurately predicted the presence or absence of occult malignancy in 7 (64%) patients. Second-look laparotomy confirmed the monoclonal antibody scan results in the patients with colorectal cancer, and magnetic resonance imaging confirmed metastatic breast cancer. This study demonstrates that In-ZCE-025 can localize occult carcinoma and may assist the surgeon in facilitating the operative exploration. In-ZCE-025 assisted in the initiation of adjuvant therapy for the patient with breast cancer.

(Arch Surg. 1990;125:866-870)